Drug intelligence / Profile preview

LAUR-401

Development stage: Preclinical
Lead developer: Lauren Sciences
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LAUR-401 is a preclinical **V-Smart nanoparticle nanomedicine** being developed by Lauren Sciences for **glioblastoma multiforme** and other forms of brain cancer centered on **GBM tumor cells**. The product appears to be a **nanoparticle formulation of irinotecan** designed for central nervous system delivery using the company's V-Smart platform. Its intended antitumor activity is driven by the **irinotecan payload**, which exerts cytotoxic effects through inhibition of **topoisomerase I** after delivery to tumor tissue. Based on the company pipeline information provided, LAUR-401 remains in **preclinical development**.

Other names: V-Smart irinotecan nanomedicineirinotecan V-Smart nanoparticle

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on LAUR-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAUR-401.

Explore the full profile